The SRC gene encodes pp60c-Src, a 60 kDa non-receptor tyrosine kinase that is frequently activated and/or overexpressed in many cancers including colon cancer. In a subset of colon cancer cell lines, it has been shown, that the overexpression of c-Src can be explained, in part, by the transcriptional activation of the SRC gene. As a result, the general goal of this thesis was to further characterize how SRC is transcriptionally regulated in human cancer cell lines. Two highly dissimilar promoters, the housekeeping-like SRC1A promoter, as well as the HIF-1Ñ regulated tissue-specific SRC1Ñ promoter, regulate SRC expression. hnRNP K and the Sp family of factors regulate the SRC1A promoter; however, the true impact of Sp3 on SRC1A activity was not understood. In this thesis, a comprehensive analysis of the effect of Sp3 on SRC1A activity was performed. Physiologically, Sp3 exists as four translational isoforms that, in part, dictate the activation potential of Sp3. In general, the longer forms of Sp3 were modest transcriptional activators of the SRC1A promoter whereas the shorter forms were unable to activate the SRC1A promoter. An analysis of all Sp3 isoforms identified that the shorter Sp3 isoforms could be converted into transcriptional activators of SRC1A if the SUMOylation of a critical lysine residue within the inhibitory domain was prevented. Conversely, SUMOylation of the same isoform had little effect on the activation potential of the longer Sp3 isoforms at the SRC1A promoter. These results suggest that transcriptional activation by Sp3 is promoter context-, isoform- and modification-dependent.<p>SRC is transcriptionally repressed by histone deacetylase inhibitors (HDIs) and despite unsuccessful studies attempting to identify HDI-responsive elements within the SRC promoter regions none could be identified. This finding also suggests that histone deacetylases (HDACs) may be required for SRC expression. Historically, it was believed that HDIs act at the histone level to alter chromatin dynamics through the inactivation of HDACs to result in histone hyperacetylation and increased transcriptional activation. As such, a systematic investigation of the changes in histone H3 and H4 acetylation status at the transcriptionally repressed SRC promoter regions and the transcriptionally activated p21WAF1 promoter region was performed. The p21WAF1 promoter was used as control in this study as p21WAF1 is a classical example of a gene transcriptionally activated by HDIs. Interestingly, similar changes in histone acetylation at the p21WAF1 promoter and both SRC promoter regions were observed. Upon closer examination of acetylation changes at discreet histone residues, it was observed that in the rare case that a particular residue was differentially acetylated upon treatment at the promoter regions analyzed, the SRC1Ñ and p21WAF1 promoter regions demonstrated more similar changes in acetylation as compared to SRC1A. Taken together, these results suggest that histone acetylation status is not an accurate indicator of transcriptional activity following HDI treatment. To further investigate HDI-mediated SRC repression, RNA Pol. II occupancy at the promoter and regions downstream of the promoter were assessed. Despite the continued occupancy of RNA Pol. II at the promoter regions, RNA Pol. II was lost from the 3¡¦ UTR upon treatment with HDIs. These findings suggest that RNA Pol. II . may be sequestered at the promoter regions upon treatment with HDIs possibly as a result of impeded transcription initiation and/or elongation. Further analysis of the phosphorylation status of RNA Pol. II identified that transcriptional initiation was indeed occurring despite HDI treatment; however, productive transcriptional elongation could not be confirmed thus suggesting a role for abrogated elongation in HDI mediated SRC repression. Complimentary analysis of the effects of HDACs on SRC expression suggested that while class I HDACs abrogated SRC expression, class II HDACs were required for the maintenance of SRC transcript levels in a promoter-independent fashion. Together, these results provide the basis for a model whereby HDIs repress SRC transcriptional expression through the inhibition of class II HDAC activity to eventually result in curtailed SRC transcriptional elongation.

The SRC gene encodes pp60c-Src, a 60 kDa non-receptor tyrosine kinase that is frequently activated and/or overexpressed in many cancers including colon cancer. In a subset of colon cancer cell lines, it has been shown, that the overexpression of c-Src can be explained, in part, by the transcriptional activation of the SRC gene. As a result, the general goal of this thesis was to further characterize how SRC is transcriptionally regulated in human cancer cell lines. Two highly dissimilar promoters, the housekeeping-like SRC1A promoter, as well as the HIF-1Ñ regulated tissue-specific SRC1Ñ promoter, regulate SRC expression. hnRNP K and the Sp family of factors regulate the SRC1A promoter; however, the true impact of Sp3 on SRC1A activity was not understood. In this thesis, a comprehensive analysis of the effect of Sp3 on SRC1A activity was performed. Physiologically, Sp3 exists as four translational isoforms that, in part, dictate the activation potential of Sp3. In general, the longer forms of Sp3 were modest transcriptional activators of the SRC1A promoter whereas the shorter forms were unable to activate the SRC1A promoter. An analysis of all Sp3 isoforms identified that the shorter Sp3 isoforms could be converted into transcriptional activators of SRC1A if the SUMOylation of a critical lysine residue within the inhibitory domain was prevented. Conversely, SUMOylation of the same isoform had little effect on the activation potential of the longer Sp3 isoforms at the SRC1A promoter. These results suggest that transcriptional activation by Sp3 is promoter context-, isoform- and modification-dependent.<p>SRC is transcriptionally repressed by histone deacetylase inhibitors (HDIs) and despite unsuccessful studies attempting to identify HDI-responsive elements within the SRC promoter regions none could be identified. This finding also suggests that histone deacetylases (HDACs) may be required for SRC expression. Historically, it was believed that HDIs act at the histone level to alter chromatin dynamics through the inactivation of HDACs to result in histone hyperacetylation and increased transcriptional activation. As such, a systematic investigation of the changes in histone H3 and H4 acetylation status at the transcriptionally repressed SRC promoter regions and the transcriptionally activated p21WAF1 promoter region was performed. The p21WAF1 promoter was used as control in this study as p21WAF1 is a classical example of a gene transcriptionally activated by HDIs. Interestingly, similar changes in histone acetylation at the p21WAF1 promoter and both SRC promoter regions were observed. Upon closer examination of acetylation changes at discreet histone residues, it was observed that in the rare case that a particular residue was differentially acetylated upon treatment at the promoter regions analyzed, the SRC1Ñ and p21WAF1 promoter regions demonstrated more similar changes in acetylation as compared to SRC1A. Taken together, these results suggest that histone acetylation status is not an accurate indicator of transcriptional activity following HDI treatment. To further investigate HDI-mediated SRC repression, RNA Pol. II occupancy at the promoter and regions downstream of the promoter were assessed. Despite the continued occupancy of RNA Pol. II at the promoter regions, RNA Pol. II was lost from the 3¡¦ UTR upon treatment with HDIs. These findings suggest that RNA Pol. II . may be sequestered at the promoter regions upon treatment with HDIs possibly as a result of impeded transcription initiation and/or elongation. Further analysis of the phosphorylation status of RNA Pol. II identified that transcriptional initiation was indeed occurring despite HDI treatment; however, productive transcriptional elongation could not be confirmed thus suggesting a role for abrogated elongation in HDI mediated SRC repression. Complimentary analysis of the effects of HDACs on SRC expression suggested that while class I HDACs abrogated SRC expression, class II HDACs were required for the maintenance of SRC transcript levels in a promoter-independent fashion. Together, these results provide the basis for a model whereby HDIs repress SRC transcriptional expression through the inhibition of class II HDAC activity to eventually result in curtailed SRC transcriptional elongation.

Cancer represents the second leading cause of death in the United States. For many malignancies, currently available treatment options offer little long-lasting survival benefits to patients. However, recent studies have shown immunotherapeutic approaches to be an attractive strategy to cancer treatment. While many current immunotherapeutic strategies convey durable responses, such responses are only seen in a minority of patients. An increased understanding of the mechanisms governing tumor immunogenicity and the biology of immune responses is crucial to improving upon the efficacy of current and future cancer immunotherapies. Histone deacetylases (HDACs), enzymes classically associated with regulation of gene expression, have been therapeutic targets in various cancers for several years due to their involvement in cell growth. However, it has become increasingly clear that HDACs are intimately involved in regulating both the immunogenicity of tumor cells and immune response of leukocytes and lymphocytes. In order to expand upon this growing knowledge, the therapeutic efficacy of the pan-HDAC inhibitor LBH589 in the treatment of melanoma was studied. The results presented here demonstrate that LBH589 is a potent inhibitor of growth in a wide variety of melanomas through induction of cell cycle arrest and apoptosis. Additionally, LBH589 increases the immune visibility of melanoma cells by increasing expression of several immune associated cell surface markers (e.g. MHC I, MHC II, CD80, CD86) in addition to upregulating expression of melanoma differentiation antigens. Furthermore, LBH589 treatment of immune cells results in an enhanced pro-inflammatory phenotype of both APCs and T-cells. These combined effects result in better activation of T-cells and ultimately prolonged survival in LBH589 treated, melanoma-baring mice. To further the understanding of the role of individual HDACs in the T-cell response, the biology of the newest HDAC, HDAC11, was further assessed. To this end, it is shown that HDAC11 is differentially expressed in T-cell populations, and expression is rapidly decreased following activation. Utilizing an HDAC11 knockout (HDAC11KO) mouse strain, it is found that both CD4+ and CD8+ T-cells lacking HDAC11 have an enhanced type 1 effector function characterized by increased proliferation and secretion of IL-2, TNF and IFN-γ. Additionally, HDAC11KO CD8+ T-cells have increased expression of both granzyme B and perforin. HDAC11KO T-cells also demonstrate enhanced resistance to inhibition by Tregs and anergy formation. As a possible mechanism for the observed phenotype, it is also demonstrated that HDAC11KO T-cells produce elevated levels of the transcription factors Eomes and T-bet, both at the basal state and post-activation. In vivo, T-cells lacking HDAC11 have a more potent and robust ability to cause GvHD and mediate an enhanced anti-tumor response. Collectively, these results demonstrate that targeting of HDACs is a viable approach to cancer immunotherapy, and that targeting of specific HDACs may be an attractive strategy for optimizing immunotherapy efficacy while minimizing side effects.

Histone deacetylases (HDAC) 1 and 2 play crucial role in chromatin remodeling and gene expression regimes, as part of multiprotein corepressor complexes. Protein kinase CK2-driven phosphorylation of HDAC1 and 2 regulates their catalytic activities and is required to form the corepressor complexes. Phosphorylation-mediated differential distributions of HDAC1 and 2 complexes in regulatory and coding regions of transcribed genes catalyze the dynamic protein acetylation of histones and other proteins, thereby influence gene expression. During mitosis, highly phosphorylated HDAC1 and 2 heterodimers dissociate and displace from mitotic chromosomes. Our goal was to identify the kinase involved in mitotic phosphorylation of HDAC1 and 2. We postulated that CK2-mediated increased phosphorylation of HDAC1 and 2 leads to dissociation of the heterodimers, and, the mitotic chromosomal exclusions of HDAC1 and 2 are largely due to the displacement of HDAC-associated proteins and transcription factors, which recruit HDACs, from chromosomes during mitosis. We further explored the role of un- or monomodified HDAC1 and 2 complexes in immediate-early genes (IEGs), FOSL1 (FOS-like antigen-1) and MCL1 (Myeloid cell leukemia-1), regulation. Dynamic histone acetylation is an important regulator of these genes that are overexpressed in a number of diseases and cancers. We hypothesized that transcription dependent recruitment of HDAC1 and 2 complexes over the gene body regions plays a regulatory role in transcription and splicing regulation of these genes. We present evidence that CK2-catalyzed increased phosphorylation of HDAC1 and 2 regulates the formation of distinct corepressor complexes containing either HDAC1 or HDAC2 homodimers during mitosis, which might target cellular factors. Furthermore, the exclusion of HDAC-recruiting proteins is the major factor for their displacement from mitotic chromosomes. We further demonstrated that un- or monophosphorylated HDAC1 and 2 are associated with gene body of FOSL1 in a transcription dependent manner. However, HDAC inhibitors prevented FOSL1 activation independently of the nucleosome response pathway, which is required for IEG induction. Interestingly, our mass spectrometry results revealed that HDAC1 and 2 interact with a number of splicing proteins, in particular, with serine/arginine-rich splicing factor 1 (SRSF1). HDAC1 and 2 are co-occupied with SRSF1 over gene body regions of FOSL1 and MCL1, regardless of underlying splicing mechanisms. Using siRNA-mediated knockdown approaches and HDAC inhibitors, we demonstrated that alternative splicing of MCL1 is regulated by RNA-directed localized changes in the histone acetylation levels at the alternative exon. The change in histone acetylation levels correlates with the increased transcription elongation and results in change in MCL1 splicing by exon skipping mechanism. Taken together, our results contribute to further understanding of how the multi-faceted HDAC1 and 2 complexes can be regulated and function in various processes, including, but not limited to, transcription regulation and alternative splicing. This can be an exciting area of future research for therapeutic interventions.

Histone deacetylases (HDAC) 1 and 2 play crucial role in chromatin remodeling and gene expression regimes, as part of multiprotein corepressor complexes. Protein kinase CK2-driven phosphorylation of HDAC1 and 2 regulates their catalytic activities and is required to form the corepressor complexes. Phosphorylation-mediated differential distributions of HDAC1 and 2 complexes in regulatory and coding regions of transcribed genes catalyze the dynamic protein acetylation of histones and other proteins, thereby influence gene expression. During mitosis, highly phosphorylated HDAC1 and 2 heterodimers dissociate and displace from mitotic chromosomes. Our goal was to identify the kinase involved in mitotic phosphorylation of HDAC1 and 2. We postulated that CK2-mediated increased phosphorylation of HDAC1 and 2 leads to dissociation of the heterodimers, and, the mitotic chromosomal exclusions of HDAC1 and 2 are largely due to the displacement of HDAC-associated proteins and transcription factors, which recruit HDACs, from chromosomes during mitosis. We further explored the role of un- or monomodified HDAC1 and 2 complexes in immediate-early genes (IEGs), FOSL1 (FOS-like antigen-1) and MCL1 (Myeloid cell leukemia-1), regulation. Dynamic histone acetylation is an important regulator of these genes that are overexpressed in a number of diseases and cancers. We hypothesized that transcription dependent recruitment of HDAC1 and 2 complexes over the gene body regions plays a regulatory role in transcription and splicing regulation of these genes. We present evidence that CK2-catalyzed increased phosphorylation of HDAC1 and 2 regulates the formation of distinct corepressor complexes containing either HDAC1 or HDAC2 homodimers during mitosis, which might target cellular factors. Furthermore, the exclusion of HDAC-recruiting proteins is the major factor for their displacement from mitotic chromosomes. We further demonstrated that un- or monophosphorylated HDAC1 and 2 are associated with gene body of FOSL1 in a transcription dependent manner. However, HDAC inhibitors prevented FOSL1 activation independently of the nucleosome response pathway, which is required for IEG induction. Interestingly, our mass spectrometry results revealed that HDAC1 and 2 interact with a number of splicing proteins, in particular, with serine/arginine-rich splicing factor 1 (SRSF1). HDAC1 and 2 are co-occupied with SRSF1 over gene body regions of FOSL1 and MCL1, regardless of underlying splicing mechanisms. Using siRNA-mediated knockdown approaches and HDAC inhibitors, we demonstrated that alternative splicing of MCL1 is regulated by RNA-directed localized changes in the histone acetylation levels at the alternative exon. The change in histone acetylation levels correlates with the increased transcription elongation and results in change in MCL1 splicing by exon skipping mechanism. Taken together, our results contribute to further understanding of how the multi-faceted HDAC1 and 2 complexes can be regulated and function in various processes, including, but not limited to, transcription regulation and alternative splicing. This can be an exciting area of future research for therapeutic interventions.

Thesis (Ph. D.)--University of Alabama at Birmingham, 2008. / Title from first page of PDF file (viewed Feb. 13, 2009). Includes bibliographical references (p. 73-93).

Thesis (Ph.D.) -- University of Texas Southwestern Medical Center at Dallas, 2005. / Embargoed. Vita. Bibliography: 170-172.

Thesis (Ph.D.)--University of Wisconsin--Madison, 2006 / eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references.

Thesis (Ph.D.)--Medical University of Ohio, 2005. / "In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Medical Sciences." Major advisor: Manohar Ratnam. Includes abstract. Document formatted into pages: iv, 158 p. Title from title page of PDF document. Title at ETD Web site: Modulation of folate receptor beta for drug targeting in acute myelogenous leukemia. Non-Latin script record Bibliography: pages 67-70, 106-109, 127-156.

Thesis (Ph.D.)--University of Wisconsin--Madison, 2006 / Includes bibliographical references. Also available on the Internet.